AACR 2025: Rapid Discovery of Tumor-Targeting Antibodies via Single-Cell Screening on the Bruker Beacon® Platform
AACR 2025 – Heading to AACR Annual Meeting in Chicago ?
Come meet our Chief Scientific Officer Jacques Fieschi-Méric and VP Business Development Nathalie Joly !
Find them at the Janvier Group Biosciences Booth #538 to connect.
🔬 From discovery and engineering to pharmacological validation MImAbs SAS brings its full expertise, experience, flexibility, and passion to support the development of your antibody-based therapeutic agents.
Jacques and Nathalie will be available to discuss our integrated solutions to advance your antibody development programs.
📌 Don’t miss our poster :
Poster hashtag#LB003 – “Rapid Single-Cell Discovery of Tumor-Targeting Antibodies Using the Bruker Beacon® Platform for Therapeutic Development”
📍 Poster Section 50, Board 3
We’re also proud to have contributed to two posters presented by XenTech : 🔹 Poster #44 – “PDX-derived cellular models for pharmacological screening and functional studies”
📍 Poster Section 2, Board 23
🔹 Poster #1289 – “A preclinical platform of PDX breast cancer models and their cellular counterparts to identify resistance mechanisms and novel therapeutic options”
📍 Poster Section 3, Board 22
If you’re interested in learning more or discussing potential collaborations, feel free to 𝗿𝗲𝗮𝗰𝗵 𝗼𝘂𝘁 𝘁𝗼 𝘂𝘀 𝘁𝗼 𝘀𝗰𝗵𝗲𝗱𝘂𝗹𝗲 𝗮 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 𝗱𝘂𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗰𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 we’d be happy to connect !
#AACR2025 #AntibodyDiscovery #CancerResearch #SingleBCellScreening
#BeaconPlatform #Bruker #ImmunoOncology #TranslationalResearch #MImAbs